omniture
上海瑛派药业有限公司 Shanghai Yingpai Pharmaceutical Co. LTD

Latest News

Impact Therapeutics Entered into Global Partnership with Eikon Therapeutics to Develop and Commercialize PARP1 Selective Inhibitors

SHANGHAI and HAYWARD, Calif., June 1, 2023 /PRNewswire/ -- IMPACT Therapeutics ("Impact"), a biopha...

2023-06-01 20:30 2307

IMPACT 2021 R&D Day: Synthetic Lethality Provides a New Platform for Targeted Cancer Therapy

SHANGHAI, Dec. 6, 2021 /PRNewswire/ -- The 2nd R&D Day event of IMPACT Therapeutics (IMPACT) succes...

2021-12-06 16:03 1475

IMPACT Therapeutics Announced ATR Inhibitor IMP9064 IND Clearance by FDA

SHANGHAI, Oct. 29, 2021 /PRNewswire/ -- IMPACT Therapeutics announced that its ATR inhibitor IMP906...

2021-10-29 14:12 1448

Impact Therapeutics Announced First-Patient-Dose of Wee1 Inhibitor IMP7068 in the U.S.

SHANGHAI, March 10, 2021 /PRNewswire/ -- Impact Therapeutics announced today that the first patient...

2021-03-10 21:14 1548